Pharming, Sanofi Extend Partnership to Manufacture Ruconest

Pharming, Sanofi Extend Partnership to Manufacture Ruconest

315168

Pharming, Sanofi Extend Partnership to Manufacture Ruconest

Pharming Group and Sanofi have renewed an agreement for the manufacturing of Ruconest (conestat alfa), Pharming’s approved treatment for swelling attacks in people with hereditary angioedema (HAE). The two companies have been working together for more than a decade, and now have agreed to extend the collaboration for the next five years. “We are very pleased to renew our long-standing downstream processing partnership with Sanofi,” Sijmen de Vries, Pharming’s CEO, said in a press release.…

You must be logged in to read/download the full post.